DNA vaccination in oncology: Current status, opportunities and perspectives

Current Clinical Pharmacology

Volumn 5, Issue 3, 2010, Pages 218-225

  van den Berg, Joost H ^a   Oosterhuis, Koen ^a   Beijnen, Jos H ^a,b   Nuijen, Bastiaan ^a   Haanen, John B A G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adjuvants; Carriers; Dermal delivery; DNA vaccination; Tumor vaccination

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CALRETICULIN; DNA VACCINE; GLYCOPROTEIN GP 100; GLYCOSAMINOGLYCAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 70; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PLASMID VECTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DNA IMMUNIZATION; DNA TRANSFECTION; DNA TRANSFER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; GENE GUN IMMUNIZATION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; JET INJECTOR; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR CELL;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; NEOPLASMS; VACCINATION; VACCINES, DNA;

EID: 78649265589     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791498734     Document Type: Article

References (96)

1. Diebold SS. Activation of dendritic cells by toll-like receptors and C-type lectins. Handb Exp Pharmacol 2009; 3-30
2. Jensen PE. Recent advances in antigen processing and presentation. Nat Immunol 2007; 8: 1041-8
3. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26: 4978-83
4. Metzger W, Mordmueller BG, Vaccines for preventing smallpox.Cochrane, Database Syst Rev 2007;CD004913
5. Wolkers MC, Toebes M, Okabe M, Haanen JB, Schumacher TN. Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol 2002; 168: 4998-5004.
6. Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M, Riviere I. Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine 2007; 25: 5013-24.
7. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008; 8: 607-18.
8. Bins AD, Wolkers MC, van dB, Haanen JB, Schumacher TN. In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 2007;179: 2126-33.
9. Fu TM, Ulmer JB, Caulfield MJ, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3: 362-71.
10. Ulmer JB, Deck RR, Dewitt CM, Donnhly JI, Liu MA. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by nonmuscle cells. Immunology 1996; 89: 59-67.
11. Spagnoli GC, Adamina M, Bolli M, et al. Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. World J Surg 2005; 29: 692-9.
12. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-68.
13. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
14. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 4156-60.
15. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
16. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008; 26: 5896-903
17. Michaluart P, Abdallah KA, Lima FD, et al. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Gene Ther 2008; 15: 676-84.
18. Peng S, Tomson TT, Trimble C, et al. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 2006; 13: 257-65.
19. Xu ZL, Mizuguchi H, Ishii-Watabe A, et al. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 2001;272: 149-56.
20. Sun J, Li D, Hao Y, et al. Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy. DNA Cell Biol 2009; 28: 233-40.
21. Hsu KF, Hung CF, Cheng WF, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001; 8: 376-83.
22. Rice J, Buchan S, Stevenson FK. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol 2002; 169: 3908-13.
23. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005; 7: 3-17.
24. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006; 13: 194-202.
25. Xu R, Megati S, Roopchand V, et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008; 26: 4819-29.
26. Lodmell DL, Ray NB, Ulrich JT, Ewalt LC, DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL), Vaccine 2000;18:1059-66.
27. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 2006; 24: 1958-65.
28. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004; 22: 1799-809.
29. Zhang A, Jin H, Zhang F, et al. Effects of multiple copies of CpG on DNA vaccination. DNA Cell Biol 2005; 24: 292-8.
30. van den Berg JH, Nuijen B, Schumacher TN, et al. Synthetic vehicles for DNA vaccination. J Drug Target 2010; 18: 1-14.
31. De Smedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res 2000; 17: 113-26.
32. El Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004; 94: 1-14.
33. Jilek S, Merkle HP, Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 2005; 57: 377-90.
34. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine based non-viral gene delivery systems. Eur J Pharm Biopharm 2005; 60: 247-66.
35. Crook K, McLachlan G, Stevenson BJ, Porteous DJ. Plasmid DNA molecules complexed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolisation. Gene Ther 1996; 3: 834-9.
36. Goh SL, Murthy N, Xu M, Frechet JM. Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development. Bioconjug Chem 2004; 15: 467-74.
37. Song YK, Liu F, Liu D. Enhanced gene expression in mouse lung by prolonging the retention time of intravenously injected plasmid DNA. Gene Ther 1998; 5: 1531-7.
38. Thierry AR, Lunardi-Iskandar Y, Bryant JL, et al. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 1995; 92: 9742-6.
39. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin and caveolae mediated endocytosis. Biochem J 2004; 377: 159-69.
40. van der Aa MA, Huth US, Hafele SY, et al. Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells. Pharm Res 2007; 24: 1590-8.
41. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci USA 1996; 93: 12349-54.
42. Ruponen M, Ronkko S, Honkakoski P, et al. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J Biol Chem 2001; 276: 33875-80.
43. Ruponen M, Honkakoski P, Tammi M, Urtti A. Cell-surface glycosaminoglycans inhibit cation-mediated gene transfer. J Gene Med 2004; 6: 405-14.
44. van den Berg JH, Oosterhuis K, Hennink WE, et al. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity, J Control Release 2009;in press.
45. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005; 298: 315-22.
46. Jilek S, Ulrich M, Merkle HP, Walter E. Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm Res 2004; 21: 1240-7.
47. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7.
48. Porteous DJ, Dorin JR, McLachlan G, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 210-8.
49. Galanis E, Hersh EM, Stopeck AT, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17: 3313-23.
50. Christensen D, Korsholm KS, Rosenkrands I, et al, Cationic liposomes as vaccine adjuvants, Expert Rev Vaccines 2007;6:785-796.
51. Zhang S, Xu Y, Wang B, et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004; 100: 165-80.
52. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 1994; 11: 1127-31.
53. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 2008; 126: 97-110.
54. Pitard B, Pollard H, Agbulut O, et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Hum Gene Ther 2002; 13: 1767-75.
55. Pitard B, Bello-Roufai M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 2004; 32: e159.
56. Heller LC, Jaroszeski MJ, Coppola D, et al. Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther 2007; 14: 275-80.
57. Maruyama H, Miyazaki J, Gejyo F. Epidermis-targeted gene transfer using in vivo electroporation. Methods Mol Biol 2005; 289: 431-6.
58. Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 2007; 25: 2064-73.
59. Roos AK, Moreno S, Leder C et al. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 2006; 13: 320-7.
60. Klinman DM, Sechler JM, Conover J, Gu M, Rosenberg AS. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J Immunol 1998; 160: 2388-92.
61. Steitz J, Britten CM, Wolfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 2006; 55: 246-53.
62. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5: 905-16.
63. Bahloul C, Taieb D, Diouani MF, et al. Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 2006; 24: 1063-72.
64. Zhou Q, Wang F, Yang F, et al. Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant. Vaccine 2009.
65. Bins AD, Jorritsma A, Wolkers MC, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11: 899-904
66. Andre F, Mir LM, DNA electrotransfer: its principles and an updated review of its therapeutic applications, Gene Ther 2004;11 Suppl 1:S33-S42.
67. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148-57.
68. Dincer Z, Jones S, Haworth R. Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Exp Toxicol Pathol 2006; 57: 351-7.
69. Ito K, Ito K, Shinohara N, Kato S. DNA immunization via intra-muscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 2003; 39: 847-54.
70. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebocontrolled phase 1b clinical trial. Vaccine 2009; 27: 2506-12.
71. Wang S, Joshi S, Lu S. Delivery of DNA to skin by particle bombardment. Methods Mol Biol 2004; 245: 185-96.
72. van den Berg JH, Nujien B, Beijnen JH, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009; 20: 181-9.
73. Verstrepen BE, Bins AD, Rollier CS, et al. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine 2008; 26: 3346-51.
74. Quaak SG, van den Berg JH, Oosterhuis K, et al. DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms. J Control Release 2009; 139: 153-9.
75. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-8.
76. Liu Z, Li X, Qiu L, et al. Treg suppress CTL responses upon immunization with HSP gp96. Eur J Immunol 2009; 39: 3110-20.
77. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006; 119: 254-64.
78. Liu X, Newton RC, Friedman SM, Scherle PA. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 938-52.
79. Lob S, Konigsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58: 153-7.
80. Kanitakis J. Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol 2002; 12: 390-9.
81. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epider mal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010; 16(2): 224-7.
82. van Oijen M, Bins A, Elias S, et al. On the role of melanomaspecific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 2004; 10: 4754-60.
83. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56: 739-45.
84. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002; 188: 136-46.
85. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010; 11: 21-7.
86. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self antigen and inhibits prostate cancer growth, Mol Ther 2009; 17: 1101-8.
87. Howley PM, Schlegel R. The human papillomaviruses. An overview. Am J Med 1988; 85: 155-8.
88. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
89. Cassaday RD, Sondel PM, King DM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007; 13: 540-9.
90. Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003; 14: 709-14.
91. Tagawa ST, Lee P, Snively J, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003; 98: 144-54.
92. Triozzi PL, Aldrich W, Allen KO, et al. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother (1997) 2005; 28: 382-8.
93. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91: 688-94.
94. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27: 4047-54.
95. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-78.
96. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15: 361-7.